PARP与免疫检查点抑制剂联合用于卵巢癌治疗
Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
作者信息
Lee Elizabeth K, Konstantinopoulos Panagiotis A
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
出版信息
Trends Cancer. 2019 Sep;5(9):524-528. doi: 10.1016/j.trecan.2019.06.004. Epub 2019 Jul 15.
Recent studies have demonstrated that, besides direct cytotoxic effects, poly(ADP ribose) polymerase (PARP) inhibitors (PARPis) exhibit antitumor immunity that occurs in a stimulator of interferon genes (STING)-dependent manner and is augmented by immune checkpoint blockade (CPB). In ovarian cancer, combined PARP and immune checkpoint inhibition has yielded encouraging preliminary results in two early-phase clinical trials and is currently being evaluated in both first-line and recurrent settings.
最近的研究表明，除了直接的细胞毒性作用外，聚（ADP核糖）聚合酶（PARP）抑制剂（PARPis）还具有抗肿瘤免疫作用，这种作用以干扰素基因刺激物（STING）依赖性方式发生，并通过免疫检查点阻断（CPB）增强。在卵巢癌中，PARP与免疫检查点抑制联合使用在两项早期临床试验中取得了令人鼓舞的初步结果，目前正在一线和复发情况下进行评估。
Zotero 插件